Neuroscience Start-up Bexorg Secures $42.5 Million in Funding
Neuroscience start-up Bexorg has raised $42.5 million in a series A funding round to develop new drug targets using donated human brains and artificial intelligence.
The company aims to address the challenge of finding effective treatments for neurodegenerative diseases, with most drug candidates failing to reach regulatory approval, a phenomenon known as the "valley of death."
According to Bexorg CEO and cofounder Zvonimir Vrselja, part of the problem is that previously, "everything that we discovered experimentally was done in simplified model systems—from cell cultures, organoids.
The start-up trains AI programs on donated human brains to develop new biomarkers and targets for neurodegenerative diseases.
Author's summary: Bexorg raises $42.5 million to use AI and donated brains for neurodegenerative disease research.
More News
- Kayla Harrison shares her true feelings about being co-main at UFC 324
- Photoshop CS6 tutorial: Color lookup
- BACK IN A BIG WAY — Turner defeats Barboza in round one
- Kayla Harrison's manager: There's a lot of beef with Ronda Rousey
- Edson Barboza Jr: Detalhes da Semana de Luta
- Kayla Harrison on UFC 324 main event order
- DHS lookup tool may expose sensitive data
- Find Out Which Infiniti Recall Affected Nearly Half A Million Cars
- Patch AM: Can Crofton wrestling turn regional realignment into a championship run?
- Kayla Harrison ‘grudge match’ backed to do bigger numbers than Khabib Nurmagomedov vs Conor McGregor